SCHEMBL143932

SCHEMBL143932

COc1ccc(-c2cc(C(=O)O)c3[nH]c4nc(OC)ccc4c3n2)cc1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 2/20 0.82
KDM4E B2RXH2 4/20 0.49
PLA2G2A P14555 5/20 0.48
SMN1; SMN2 Q16637 3/20 0.47
MAPT P10636 2/20 0.47
ALDH1A1 P00352 2/20 0.47
NPC1 O15118 1/20 0.47
LMNA P02545 1/20 0.47
HPGD P15428 1/20 0.47
NFKB1 P19838 1/20 0.47
RAB9A P51151 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
ATM Q13315 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
PDE10A Q9Y233 2/20 0.46
ALPL P05186 1/20 0.44
CA9 Q16790 1/20 0.44
KLK7 P49862 2/20 0.43
EPRS1 P07814 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL144466 0.91 JAK2 (0.82) JAK2KDM4EPLA2G2ASMN1; SMN2MAPT
SCHEMBL142279 0.90 JAK2 (1.00) JAK2KDM4EPLA2G2AALDH1A1NPC1
SCHEMBL142655 0.83 JAK2 (0.78) JAK2KDM4EPLA2G2ASMN1; SMN2MAPT
SCHEMBL178707 0.83 JAK2 (0.69) JAK2KDM4EMAPTALDH1A1NPC1
SCHEMBL141522 0.76 JAK2 (0.80) JAK2KDM4EPLA2G2ASMN1; SMN2MAPT
SCHEMBL143862 0.74 JAK2 (1.00) JAK2KDM4EPLA2G2AALDH1A1LMNA
SCHEMBL142463 0.73 JAK2 (0.77) JAK2PLA2G2A
SCHEMBL141989 0.71 JAK2 (0.68) JAK2
SCHEMBL5525815 0.71 PDE10A (0.65) KDM4EPLA2G2ASMN1; SMN2MAPTALDH1A1
SCHEMBL3234823 0.70 AURKA (0.65) KDM4EPLA2G2ASMN1; SMN2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 EP disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 EP disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
EP-2370407-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 JAK2 1/4885KDM4E 928/4885PLA2G2A 4509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.